开发下一代 ADC,新锐融资1.2亿美元,默沙东支持

动脉网
Nov 19

Solve Therapeutics,一家开发实体瘤ADC药物的生物技术公司,宣布完成1.2亿美元超额认购融资,此轮融资由Yosemite领投,Alexandria Venture Investments、默沙东等多家机构参投,未提及财务顾问。该公司由行业资深领导者于2021年创立,已累计融资3.21亿美元(2022年12月A轮融资1.26亿美元,2024年12月融资7500万美元)。其核心技术...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10